$Abcam plc(ABCM)$ Unfortunately seems like a less known biotech company.  As someone using their products on a regular basis, the company is known in the research community for their quality products. It is a well-established company and although quite limited in their product portfolio, they do have uniqueness. I am just surprised that so many of the biotech companies that are literary just “selling” an idea (= candidate drug in clinical trials and many many years away from a potential product) or relatively new companies like Twist bioscience (which is as limited as Abcam in their product profile) have such high trading volumes. Just wondering why, the trading volume of Abcam is low.